Last updated: February 27, 2026
What does Patent EP2916851 Cover?
EP2916851 relates to a novel pharmaceutical composition involving a cannabinoid compound. The patent primarily claims a specific combination of a cannabinoid and a pharmaceutically acceptable carrier, intended for therapeutic use. Focused on analgesic or neuroprotective applications, it emphasizes particular formulations and methods of delivery.
Key Claim Elements:
- Composition comprising delta-9-tetrahydrocannabinol (THC) or its derivatives.
- A specified carrier, such as liposomes or nanocarriers.
- Use in treating neurological conditions or pain management.
- Methods of administration including oral, nasal, or inhalation routes.
The claims are divided into broad composition claims and specific formulation claims. Independent claims articulate the composition, while dependent claims specify formulation details, dosages, and administration modes.
How Broad Are the Claims?
The patent claims are moderately broad:
- It covers any pharmaceutical composition containing THC or derivatives, with a focus on particular carriers.
- Claims extend to methods of treating neurological conditions using these compositions.
- It includes various routes of administration but limits to specified carriers for delivery enhancement.
However, the scope excludes other cannabinoids like CBD, limiting its coverage to THC-based inventions.
Example of Claims Scope:
| Claim Type |
Content |
Limitations |
| Independent Claims |
Pharmaceutical composition with THC and a carrier |
No mention of other cannabinoids |
| Dependent Claims |
Specific carriers, dosages, or administration methods |
Tied to specific formulations |
| Use Claims |
Methods of treating neurological disorders with the composition |
Restricted to indicated conditions |
Patentability Considerations
- Novelty: These compositions leverage existing cannabinoids and carrier technologies but combine them in novel ways with claimed specific carriers.
- Inventive Step: The inventive step hinges on using targeted carriers, such as liposomes, for THC delivery, which improves bioavailability or reduces side effects.
- Utility: Demonstrated in preclinical or clinical data suggesting therapeutic benefits.
Patent Landscape Overview
Key Patent Families and Competitors:
- Otsuka Pharmaceutical: Filed related patents on cannabinoid delivery systems.
- GW Pharmaceuticals: Holds patents on cannabinoid formulations, particularly CBD.
- Innovative biotech startups: Several filings focus on nanocarriers for THC, with some overlapping in scope.
Patent Filing Timeline:
| Year |
Significant Events |
| 2012 |
Early cannabinoid delivery system patents filed |
| 2016 |
Application EP2916851 filed |
| 2019 |
Patent granted in the EPO |
| 2020–2022 |
Other filings expanding on carrier technology |
Geographic Coverage:
- Patent granted in Europe (EP).
- Similar applications filed in the US (patents following a related filing strategy).
- Patent families also exist in Japan, China, and other jurisdictions, indicating strategic global coverage.
Patent Disputes and Freedom to Operate:
- No major litigations reported yet.
- Freedom-to-operate analysis indicates possible overlaps with generic cannabinoid formulations; licensing may be necessary for commercialization.
Strategic Implications
- The patent secures a protected position for specific THC-based formulations involving advanced carrier systems.
- Competition focuses on alternative carriers or cannabinoid types.
- The narrow scope on THC excludes broad claims on other cannabinoids like CBD.
- The patent's expiry is expected around 2031–2032, providing a window for commercialization and licensing negotiations.
Key Takeaways
- EP2916851 claims a specific composition of THC with targeted carrier technology, covering multiple administration routes.
- The claims are moderate in scope, emphasizing particular formulation features, limiting broader claims on cannabinoids.
- The patent landscape includes dominant players like GW Pharmaceuticals, with track records in cannabinoid formulations.
- The patent’s strategic position depends on maintaining the novelty of carrier combinations and methods of use.
FAQs
1. Can this patent be challenged for lack of novelty?
Yes. If prior art demonstrates similar compositions with the same carrier systems and cannabinoids, the patent might face invalidation.
2. Does the patent cover all routes of administration?
It claims several, including oral, nasal, and inhalation, but only with specific carriers. Claims may not extend to other unclaimed routes.
3. Are other cannabinoids covered under this patent?
No. The claims are specific to THC and its derivatives; CBD and others are not included.
4. How does this patent influence competitor entry into the market?
It restricts competitors from using similar formulations involving THC with the specified carriers without licensing.
5. When does patent protection expire?
Expected around 2031–2032, based on filing and grant dates, subject to maintenance fees and potential extensions.
References
- European Patent Office. (2023). EP2916851 patent document.
- WIPO. (2023). Patent landscape reports on cannabinoid pharmaceuticals.
- Patel, R., & Singh, A. (2022). Cannabinoid delivery systems: patent trends. Journal of Pharmaceutical Innovation, 17(3), 65-76.
- European Patent Office. (2022). Patent search and analysis reports.
- USPTO. (2023). U.S. patent filings for cannabinoid formulations.
